Trial Profile
OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2015
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Myocardial infarction
- Focus Pharmacokinetics
- 07 Sep 2015 New trial record
- 02 Sep 2015 Primary endpoint has been met. (Area under the ticagrelor plasma concentration versus time curve (AUC0-1) over 1 hour post ticagrelor administration), according to an abstract presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
- 02 Sep 2015 Primary endpoint has been met. (Ticagrelors Cmax over 1 hour post ticagrelor administration), according to an abstract presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology